WO2002024711A1 - Novel thiazole bicyclic compounds - Google Patents

Novel thiazole bicyclic compounds Download PDF

Info

Publication number
WO2002024711A1
WO2002024711A1 PCT/JP2001/008141 JP0108141W WO0224711A1 WO 2002024711 A1 WO2002024711 A1 WO 2002024711A1 JP 0108141 W JP0108141 W JP 0108141W WO 0224711 A1 WO0224711 A1 WO 0224711A1
Authority
WO
WIPO (PCT)
Prior art keywords
bicyclic compounds
aryl
novel thiazole
thiazole
acyloxy
Prior art date
Application number
PCT/JP2001/008141
Other languages
French (fr)
Japanese (ja)
Inventor
Masakazu Fujita
Tetsuya Hirayama
Yoshikazu Kawahara
Original Assignee
Nikken Chemicals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nikken Chemicals Co., Ltd. filed Critical Nikken Chemicals Co., Ltd.
Priority to AU2001290243A priority Critical patent/AU2001290243A1/en
Publication of WO2002024711A1 publication Critical patent/WO2002024711A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Thiazole bicyclic compounds represented by the following general formula (I) or (II) which are useful as the active ingredient of drugs for preventing and/or treating diseases in which TNF-a participates, stereoisomers thereof or salts of the same wherein Ar1 represents nitrogen-containing heteroaryl; Ar2 represents aryl or cycloalkyl; R?1, R2 and R3¿ represent each lower alkyl, aryl, acyl, hydroxyl, lower alkoxy, acyloxy, carboxyl or amino; n, m and p are each an integer of from 0 to 2; Q?1, Q2 and Q3¿ are each selected from the group consisting of C, CH, CH¿2?, C=O, O, N and NH; and --- represents a double or single bond.
PCT/JP2001/008141 2000-09-20 2001-09-19 Novel thiazole bicyclic compounds WO2002024711A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001290243A AU2001290243A1 (en) 2000-09-20 2001-09-19 Novel thiazole bicyclic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-285005 2000-09-20
JP2000285005 2000-09-20

Publications (1)

Publication Number Publication Date
WO2002024711A1 true WO2002024711A1 (en) 2002-03-28

Family

ID=18769142

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008141 WO2002024711A1 (en) 2000-09-20 2001-09-19 Novel thiazole bicyclic compounds

Country Status (2)

Country Link
AU (1) AU2001290243A1 (en)
WO (1) WO2002024711A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085219A1 (en) * 2004-02-27 2005-09-15 Novartis Ag Isothiourea derivatives
CN114341117A (en) * 2019-09-02 2022-04-12 默克专利有限公司 Material for organic electroluminescent device
EP4032896A1 (en) * 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07291976A (en) * 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc Imidazo (2,1-b) thiazole derivative
WO1996020710A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO1996021667A1 (en) * 1995-01-11 1996-07-18 Merck Frosst Canada Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
WO2000044756A1 (en) * 1999-01-28 2000-08-03 Takeda Chemical Industries, Ltd. Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07291976A (en) * 1994-04-27 1995-11-07 Otsuka Pharmaceut Factory Inc Imidazo (2,1-b) thiazole derivative
WO1996020710A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO1996021667A1 (en) * 1995-01-11 1996-07-18 Merck Frosst Canada Inc. Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
WO2000044756A1 (en) * 1999-01-28 2000-08-03 Takeda Chemical Industries, Ltd. Thiazolopyrimidine compounds, process for the preparation of the same and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085219A1 (en) * 2004-02-27 2005-09-15 Novartis Ag Isothiourea derivatives
CN114341117A (en) * 2019-09-02 2022-04-12 默克专利有限公司 Material for organic electroluminescent device
EP4032896A1 (en) * 2021-01-20 2022-07-27 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof
WO2022157166A1 (en) * 2021-01-20 2022-07-28 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Thiazolopyrimidones as inhibitors of ddr1/2 and therapeutic uses thereof

Also Published As

Publication number Publication date
AU2001290243A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
MXPA04001016A (en) Sulfonamide derivatives as gamma secretase inhibitors.
WO2002048157A3 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
CA2322171A1 (en) Cyclic amino compounds
NO20045369L (en) New, substituted sulfamate anticonvulsant derivatives
CA2234096A1 (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
TW200738629A (en) Ethylenediamine derivatives
DE60204452D1 (en) [1,5] pyridine derivatives
EP1312601A4 (en) Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
WO2003057225A3 (en) Phosphate transport inhibitors
EP1389463A4 (en) Medicine for inhibiting drug elimination pump
EA200400432A1 (en) UREA DERIVATIVES
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
WO2005056524A3 (en) Therapeutic agents useful for treating pain
WO2004014388A8 (en) 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
TW200510317A (en) Caspase inhibitors and uses thereof
TR200201205T2 (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
BR0310057A (en) improvement of cataract development and other ophthalmic diseases
ATE372995T1 (en) BENZO(B)(1,4)DIOXEPINE DERIVATIVES
WO2004014868A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
IL163625A0 (en) Alkoxy-pyridine derivatives and pharmaceutical compositions containing the same
EP1314719A4 (en) Benzoic acid derivatives and drugs containing the same as the active ingredient
WO2003053971A8 (en) Pyridoquinoxaline antivirals
DE60221508D1 (en) Amino acid derivatives as HIV protease inhibitors
WO2002032901A3 (en) Bridged piperazine derivatives
DE69931378D1 (en) CHINAZOLINE DERIVATIVES AND THERAPEUTIC USES THEREOF

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase